Substituted benzolactam compounds as substance P antagonists
First Claim
Patent Images
1. A compound of the formula or its pharmaceutically acceptable salt, whereinW is —
- S—
CH2—
;
R1, R2 and R3 are independently hydrogen, C1-C3 alkyl C1-C3 alkyl C1-C3 alkoxy or halo C1-C3 alkyl, provided that when W is methylene, both R2 and R3 are not hydrogen;
X is halo, C1-C3 alkoxy, C1-C3 alkyl, halo C1-C3 alkoxy or C1-C3 alkenyl;
Y is imino or oxy;
Q is oxygen or sulfur; and
T is (2S,3S)-2-diphenylmethylquinuclidin-3-yl, (2S,3S)-2-phenylpiperidin-3-yl or (2S,3S)-2-diphenylmethyl-1-azanorbornan-3-yl.
2 Assignments
0 Petitions
Accused Products
Abstract
Compounds of formula I are antagonists of Substance P and have activity against CNS and gastrointestinal disorders.
8 Citations
3 Claims
-
1. A compound of the formula
or its pharmaceutically acceptable salt, wherein W is — - S—
CH2—
;
R1, R2 and R3 are independently hydrogen, C1-C3 alkyl C1-C3 alkyl C1-C3 alkoxy or halo C1-C3 alkyl, provided that when W is methylene, both R2 and R3 are not hydrogen;
X is halo, C1-C3 alkoxy, C1-C3 alkyl, halo C1-C3 alkoxy or C1-C3 alkenyl;
Y is imino or oxy;
Q is oxygen or sulfur; and
T is (2S,3S)-2-diphenylmethylquinuclidin-3-yl, (2S,3S)-2-phenylpiperidin-3-yl or (2S,3S)-2-diphenylmethyl-1-azanorbornan-3-yl. - View Dependent Claims (2, 3)
- S—
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneePfizer Inc.
-
Original AssigneePfizer Inc.
-
InventorsWakabayashi, Hiroaki, Ikunaka, Masaya
-
Primary Examiner(s)Morris, Patricia L.
-
Application NumberUS09/605,471Time in Patent Office440 DaysField of Search544/50, 514/224.2US Class Current544/50CPC Class CodesC07D 401/12 linked by a chain containin...C07D 413/12 linked by a chain containin...C07D 417/12 linked by a chain containin...C07D 453/02 containing not further cond...
